Tenaya Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Tenaya Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.0 times its market value (net cash). Higher than 88% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-90.5×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 80% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-22.6×Operating cash was negative last year, while some debt falls due within a year.
Lower than 57% of Healthcare companies in United States.
Cash Cushion Ratio
1.0× cashCash, after subtracting all debt, is 1.0 times its market value (net cash).
Higher than 88% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Tenaya Therapeutics, Inc. made a loss over the last year. Tenaya Therapeutics, Inc. owes $0.26 for every $1 it owns. Tenaya Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossTenaya Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.25The share price is 1.25 times Tenaya Therapeutics, Inc.'s book value per share, lower than 74% of Healthcare companies in United States.
Market cap
$87 MThe total market value of all of Tenaya Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 67% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$69 MWhat Tenaya Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.31Net worth divided by the number of shares. The share price of $0.39 is 1.3 times this, which is the P/B above.
Return on equity (ROE)
-121.9%Tenaya Therapeutics, Inc. lost 121.9% of its shareholders' money over the last year, lower than 76% of Healthcare companies in United States.
Owes vs Owns
0.26×Tenaya Therapeutics, Inc. owes $0.26 for every $1 it owns (low), lower than 65% of Healthcare companies in United States.
Dividend yield
NoneTenaya Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossTenaya Therapeutics, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashTenaya Therapeutics, Inc. held $90 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Tenaya Therapeutics, Inc.: $87 M ÷ $69 M (30 Jun 2026) = 1.3.
What is Tenaya Therapeutics, Inc.'s return on equity?
Tenaya Therapeutics, Inc. lost 121.9% of its shareholders' money over the last year, lower than 76% of Healthcare companies in United States.
How much does Tenaya Therapeutics, Inc. owe compared with what it owns?
Tenaya Therapeutics, Inc. owes $0.26 for every $1 it owns (low), lower than 65% of Healthcare companies in United States.
Does Tenaya Therapeutics, Inc. pay a dividend?
No. Tenaya Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.